{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:00:34Z","timestamp":1789563634074,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Clinical Care endowment"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Historically, patients with leukaemia and invasive fusariosis (IF) have experienced poor outcomes in the setting of persistent immunosuppression. Herein, we retrospectively reviewed the incidence, presentation and outcomes of IF that are scarcely studied in contemporary cohorts of leukaemia patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified adult leukaemia patients with proven or probable IF at MD Anderson Cancer Center during 2009\u201321. Independent risk factors for 42 day mortality after IF diagnosis were determined using a multivariable logistic regression model. Combined with historical data, the annual IF incidence density over the past 23 years was estimated using Poisson regression analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 140 leukaemia patients with IF (114 proven), 118 patients (84%) had relapsed\/refractory leukaemia and 124 (89%) had neutropenia at IF diagnosis. One hundred patients (71%) had pulmonary IF, 88 (63%) had disseminated IF and 48 (34%) had fungaemia. Coinfections were common (55%). Eighty-nine patients (64%) had breakthrough IF to mould-active triazoles. Most patients (84%) received combination antifungal therapy. Neutrophil recovery [adjusted OR (aOR), 0.04; 95% CI, 0.01\u20130.14; P\u200a&amp;lt;\u200a0.0001], pulmonary IF (aOR, 3.28; 95% CI, 1.11\u20139.70; P\u200a=\u200a0.032) and high SOFA score (aOR, 1.91 per 1-point increase; 95% CI, 1.47\u20132.50; P\u200a&amp;lt;\u200a0.0001) were independent predictors of 42 day mortality outcomes. From 1998 to 2021, IF incidence density increased significantly at an annual ratio of 1.03 (95% CI, 1.01\u20131.06; P\u200a=\u200a0.04).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>IF is predominantly seen in patients with relapsed\/refractory leukaemia and increasingly seen as a breakthrough infection to mould-active triazoles. Despite frequent combination antifungal therapy, high mortality rates have persisted in patients with lasting neutropenia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad377","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T06:17:27Z","timestamp":1702275447000},"page":"297-306","source":"Crossref","is-referenced-by-count":22,"title":["Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes"],"prefix":"10.1093","volume":"79","author":[{"given":"Takahiro","family":"Matsuo","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7784-7256","authenticated-orcid":false,"given":"Sebastian","family":"Wurster","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Tarrand","sequence":"additional","affiliation":[{"name":"Section of Clinical Microbiology and Virology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-4339","authenticated-orcid":false,"given":"Russell E","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Padua , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8051-2940","authenticated-orcid":false,"given":"Dimitrios P","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"2024020113250546800_dkad377-B1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/cid\/ciu947","article-title":"Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients","volume":"60","author":"Garnica","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024020113250546800_dkad377-B2","doi-asserted-by":"crossref","first-page":"1105.e1","DOI":"10.1016\/j.cmi.2018.05.006","article-title":"Invasive mould disease in haematologic patients: comparison between fusariosis and aspergillosis","volume":"24","author":"Nucci","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2024020113250546800_dkad377-B3","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1128\/AAC.00636-16","article-title":"Antimold prophylaxis may reduce the risk of invasive fusariosis in hematologic patients with superficial skin lesions with positive culture for Fusarium","volume":"60","author":"Varon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024020113250546800_dkad377-B4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jinf.2010.01.010","article-title":"Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998\u20132009","volume":"60","author":"Campo","year":"2010","journal-title":"J Infect"},{"key":"2024020113250546800_dkad377-B5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.11510","article-title":"Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection","volume":"98","author":"Nucci","year":"2003","journal-title":"Cancer"},{"key":"2024020113250546800_dkad377-B6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1086\/383319","article-title":"Fusarium infection in hematopoietic stem cell transplant recipients","volume":"38","author":"Nucci","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024020113250546800_dkad377-B7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/1042819031000149386","article-title":"Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery","volume":"45","author":"Kontoyiannis","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"2024020113250546800_dkad377-B8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024020113250546800_dkad377-B9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) consensus group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024020113250546800_dkad377-B10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"2024020113250546800_dkad377-B11","doi-asserted-by":"crossref","first-page":"e01244-19","DOI":"10.1128\/AAC.01244-19","article-title":"Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients","volume":"63","author":"Lamoth","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024020113250546800_dkad377-B12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/myc.12538","article-title":"Radiologic findings of Fusarium pneumonia in neutropenic patients","volume":"60","author":"Sassi","year":"2017","journal-title":"Mycoses"},{"key":"2024020113250546800_dkad377-B13","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/1469-0691.12409","article-title":"Improvement in the outcome of invasive fusariosis in the last decade","volume":"20","author":"Nucci","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2024020113250546800_dkad377-B14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1086\/313918","article-title":"Significance of aspergillemia in patients with cancer: a 10-year study","volume":"31","author":"Kontoyiannis","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2024020113250546800_dkad377-B15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jinf.2013.06.004","article-title":"The diagnostic yield of skin biopsy in patients with leukemia and suspected infection","volume":"67","author":"Farmakiotis","year":"2013","journal-title":"J Infect"},{"key":"2024020113250546800_dkad377-B16","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/429921","article-title":"Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay","volume":"40","author":"Marr","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024020113250546800_dkad377-B17","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/dkx423","article-title":"Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the secure trial","volume":"73","author":"Kontoyiannis","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024020113250546800_dkad377-B18","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024020113250546800_dkad377-B19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fmb.15.34","article-title":"Isavuconazole: a new extended spectrum triazole for invasive mold diseases","volume":"10","author":"Ananda-Rajah","year":"2015","journal-title":"Future Microbiol"},{"key":"2024020113250546800_dkad377-B20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/jof3020019","article-title":"Antifungal susceptibility testing of Fusarium: a practical approach","volume":"3","author":"Al-Hatmi","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"2024020113250546800_dkad377-B21","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1517\/14656566.2015.1057500","article-title":"The \u2018cephalosporin era\u2019 of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections","volume":"16","author":"Chitasombat","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2024020113250546800_dkad377-B22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/jac\/dkaa516","article-title":"Do high MICs predict the outcome in invasive fusariosis?","volume":"76","author":"Nucci","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024020113250546800_dkad377-B23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/jof7030217","article-title":"Breakthrough mucormycosis developing on Mucorales-active antifungals portrays a poor prognosis in patients with hematologic cancer","volume":"7","author":"Axell-House","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2024020113250546800_dkad377-B24","doi-asserted-by":"crossref","first-page":"e01896-18","DOI":"10.1128\/AAC.01896-18","article-title":"Preexposure to isavuconazole increases the virulence of Mucorales but not Aspergillus fumigatus in a Drosophila melanogaster infection model","volume":"63","author":"Wurster","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024020113250546800_dkad377-B25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bjh.18445","article-title":"How are granulocytes for transfusion best used? The past, the present and the future","volume":"200","author":"Morton","year":"2023","journal-title":"Br J Haematol"},{"key":"2024020113250546800_dkad377-B26","doi-asserted-by":"crossref","first-page":"ofac535","DOI":"10.1093\/ofid\/ofac535","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) as adjuvant therapy for invasive fungal diseases","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024020113250546800_dkad377-B27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2022.06.035","article-title":"Nivolumab induces long-term remission in a patient with fusariosis","volume":"173","author":"Khatamzas","year":"2022","journal-title":"Eur J Cancer"},{"key":"2024020113250546800_dkad377-B28","doi-asserted-by":"crossref","first-page":"1018202","DOI":"10.3389\/fimmu.2022.1018202","article-title":"Checkpoint inhibitors as immunotherapy for fungal infections: promises, challenges, and unanswered questions","volume":"13","author":"Wurster","year":"2022","journal-title":"Front Immunol"},{"key":"2024020113250546800_dkad377-B29","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024020113250546800_dkad377-B30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/ciab1070","article-title":"Investigational antifungal agents for invasive mycoses: a clinical perspective","volume":"75","author":"Lamoth","year":"2022","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/2\/297\/56418214\/dkad377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/2\/297\/56418214\/dkad377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:25:36Z","timestamp":1706793936000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/2\/297\/7468707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,11]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad377","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,12,11]]}}}